Plasma choline-containing phospholipids: potential biomarkers for colorectal cancer progression |
| |
Authors: | Song Li Bin Guo Jianwen Song Xiaoli Deng Yusheng Cong Pengfei Li Ke Zhao Lihong Liu Gang Xiao Feng Xu Yingjiang Ye Zhenwen Zhao Menggang Yu Yan Xu Jianli Sang Junjie Zhang |
| |
Affiliation: | 1. Key Laboratory of Cell Proliferation and Regulation Biology, Ministry of Education, Institute of Cell Biology, College of Life Sciences, Beijing Normal University, Beijing, 100875, China 2. General Hospital of Second Artillery Force of the Chinese PLA, Beijing, 100088, China 3. Beijing Hospital, Beijing, 100730, China 4. People’s Hospital of Peking University, Beijing, 100044, China 5. Department of Obstetrics and Gynecology, Indiana University Cancer Center, Indiana University School of Medicine, 975 West Walnut Street IB355A, Indianapolis, IN, 46202, USA 6. Division of Biostatistics, Indiana University School of Medicine, 410 West 10th Street, Suite 3000, Indianapolis, IN, 46202, USA
|
| |
Abstract: | Colorectal cancer (CRC) is believed to progress through the adenoma–carcinoma sequence. The adenoma–carcinoma transition is an important window for early detection and intervention of CRC. In the present study, plasma samples from patients with CRC (n = 120), patients with adenomatous polyps (AP) (n = 120), and healthy controls (n = 120) were collected. Plasma phospholipid levels were analyzed with liquid chromatography–tandem mass spectrometry. It was found that the plasma levels of major lysophosphatidylcholine (LPC) species were gradationally decreased from healthy controls, AP to CRC subjects. A formula including total saturated LPCs, 18:2 LPC and sphingosylphosphorylcholine (SPC) yielded a sensitivity and specificity of 88.3 and 80 % for separating CRC from healthy controls. An optimized model with total saturated LPCs, 20:4 LPC and sphingomyelins (SM) as markers yielded a sensitivity and specificity of 89 and 80 % for separating AP from the healthy controls. Moreover, with SM, SPC and saturated LPCs as markers, a model was made to separate CRC from AP with the sensitivity and specificity of 90 and 92.5 %, respectively. These data indicate that the plasma choline-containing phospholipid levels represent potential biomarkers to distinguish between healthy controls, AP and CRC cases, implying their clinical usage in CRC and/or AP-CRC progression detection. |
| |
Keywords: | |
本文献已被 SpringerLink 等数据库收录! |
|